The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)

Overview

The primary objective of this trial is to evaluate the correlation between the intensity of the protein big-h3 expression at tumoural microenvironment and the TNM/UICC staging (from I to IV) of pancreatic adenocarcinoma lesion.

Full Title of Study: “The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2021

Detailed Description

The pancreatic adenocarcinoma is the most common pancreatic cancer. Currently, it represents the fourth cause of death by cancer in France. The diagnosis is often realized when the disease is at an advanced stage because of its delayed clinical expression. Only 20% of the patients are diagnosed at a stage enabling a tumour resection. Scientists discovered a protein playing a key role: the βig-h3 protein. In mouse models, this protein is present in several stages of the tumorigenesis. A mutation of the gene Kras leads to the development of PANin (Pancreatic Intraepithelial Neoplasia) type precancerous lesions. The βig-h3 protein is early and highly expressed in the stroma around these lesions and in the pancreatic adenocarcinoma stroma. Moreover, studies showed that protein neutralization leads to a tumour size reduction by increasing the CD8+anti-tumor activity. This protein is detected in the blood serum of patients suffering from a pancreatic adenocarcinoma. So, this protein which is secreted by the extracellular matrix could be a predictive marker for the pancreatic adenocarcinoma. In this prospective, multicentric non-interventional study, it is anticipated to recruit 80 patients (20 per TNM/UICC stage). Included patients will undergo two samples: A blood sample (5 ml) and a tumour sample (surgical exeresis piece or tumour tissue obtained for the initial diagnosis). In case of relapse, new samples will be performed.

Interventions

  • Procedure: Biological Samples
    • 5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy). In case of relapse, new samples will be performed (blood and tumoral samples)

Arms, Groups and Cohorts

  • Samples
    • Included patients will undergo 2 biological samples : a 5-ml blood sample included in the standard care and a tumoral sample (from the surgical exeresis or from the initial diagnosis biopsy). Patients with a confirmed pancreatic carcinoma will be followed during 18 months in this cohort. In case of relapse, patients will have 2 new biological samples (blood and tumoral).

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of the correlation between the intensity of the protein βig-h3 expression at tumoural microenvironment and the TNM/UICC (from I to IV) of pancreatic adenocarcinoma lesion
    • Time Frame: At inclusion
    • Correlation between the intensity of the protein βig-h3 expression at tumoural microenvironment and the TNM/UICC (from I to IV) of pancreatic adenocarcinoma lesionimmunohistochemical analysis of pancreatic adenocarcinoma

Secondary Measures

  • Evaluation of the correlation of βig-h3 protein blood rate and the pancreatic adenocarcinoma TNM/UICC staging
    • Time Frame: At inclusion and upon relpase assessed up to 36 months
    • Correlation between βig-h3 protein blood rate (ELISA) and the pancreatic adenocarcinoma TNM/UICC staging
  • Evaluation of the correlation between the βig-h3 protein expression intensity in the tumoural microenvironment and the immune infiltrate LT CD8+ of pancreatic adenocarcinoma
    • Time Frame: At inclusion and upon relpase assessed up to 36 months
    • Correlation between the βig-h3 protein expression intensity in the tumoural microenvironment and the immune infiltrate LT CD8+ of pancreatic adenocarcinoma
  • Evaluation of the correlation between βig-h3 protein expression intensity and patients clinical evolution
    • Time Frame: 6 months after patient’s inclusion
    • Correlation between βig-h3 protein expression intensity and patients clinical evolution (6-month objective response rate according to RECIST 1.1 criteria)
  • Evaluation of the the correlation between βig-h3 protein expression intensity and patients clinical evolution
    • Time Frame: Assessed up to 36 months
    • Correlation between βig-h3 protein expression intensity and Overall Survival
  • Evaluation of the correlation between βig-h3 protein expression intensity and patients clinical evolution
    • Time Frame: Assessed up to 36 months
    • Correlation between βig-h3 protein expression intensity and Progression Free Survival

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years at the day of consenting to the study – Patient with a potential pancreatic adenocarcinoma whatever the TNM/UICC stage – Systematic treatment not initiated – Signed and dated informed consent document. Exclusion Criteria:

  • Pregnant or breastfeeding woman – Geographical, social or psychiatric reason preventing the patient from completing the study follow-up

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Leon Berard
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • DE LA FOUCHARDIERE Christelle, Dr, Principal Investigator, Centre Leon Berard
  • Overall Contact(s)
    • BLANC Ellen, +33 4.78.78.29.67, ellen.blanc@lyon.unicancer.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.